SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 1,613,558 shares, a drop of 13.3% from the February 12th total of 1,860,014 shares. Based on an average daily volume of 281,424 shares, the days-to-cover ratio is presently 5.7 days. Currently, 4.5% of the company’s stock are sold short. Currently, 4.5% of the company’s stock are sold short. Based on an average daily volume of 281,424 shares, the days-to-cover ratio is presently 5.7 days.

SAB Biotherapeutics Price Performance

SABS stock opened at $3.70 on Thursday. The stock’s 50 day moving average is $4.03 and its two-hundred day moving average is $3.41. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a market capitalization of $188.52 million, a PE ratio of -1.59 and a beta of 0.59. The company has a quick ratio of 9.46, a current ratio of 9.46 and a debt-to-equity ratio of 0.02.

SAB Biotherapeutics (NASDAQ:SABS) last released its earnings results on Monday, March 9th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Analysts predict that SAB Biotherapeutics will post -3.69 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Wall Street Zen downgraded SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 14th. Guggenheim began coverage on SAB Biotherapeutics in a research report on Friday, December 19th. They set a “buy” rating and a $15.00 price target on the stock. UBS Group began coverage on SAB Biotherapeutics in a report on Wednesday, January 7th. They issued a “buy” rating and a $7.00 price target for the company. Chardan Capital increased their price objective on shares of SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Finally, Zacks Research lowered shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, SAB Biotherapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in SABS. Vivo Capital LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth about $22,954,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics in the third quarter worth about $8,847,000. RA Capital Management L.P. acquired a new position in SAB Biotherapeutics in the third quarter worth about $8,847,000. Woodline Partners LP acquired a new stake in SAB Biotherapeutics during the third quarter valued at approximately $5,730,000. Finally, Spruce Street Capital LP acquired a new stake in SAB Biotherapeutics during the fourth quarter valued at approximately $8,222,000. 7.82% of the stock is owned by institutional investors and hedge funds.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.